Stay updated with breaking news from Biotechnologies Aps. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Evaxion presented promising data from its Phase 1/2a clinical trial of EVX-02 in patients with late-stage melanoma at the 2023 AACR meetingEVX-03, a DNA-based personalized cancer vaccine, is expected to
Investegate announcements from Evaxion Biotech, Fourth quarter and full year 2022 financial results and business update
Hørsholm, Denmark, 18 April 2023 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS today announces that the company through its research collaboration partners at... | April 18, 2023
HØRSHOLM, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven